Niagen Bioscience is back in focus after analysts trimmed their blended price target from US$14 to around US$12.60, signaling a more measured view of potential upside. Research notes describe this ...

Investors may be wondering whether Aveanna Healthcare Holdings at US$7.72 is offering good value right now, or if recent enthusiasm has already been fully reflected in the price. The stock has moved ...